Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We began analyzing https://www.nature.com/articles/nrclinonc.2016.217, but it redirected us to https://www.nature.com/articles/nrclinonc.2016.217. The analysis below is for the second page.

Title[redir]:
Tumour-associated macrophages as treatment targets in oncology | Nature Reviews Clinical Oncology
Description:
Tumour-associated macrophages (TAMs) are key drivers of tumour-promoting inflammation and cancer progression, and are important determinants of responsiveness to a range of therapies. Herein, the authors summarize the roles of TAMs in cancer, and discuss the potential of TAM-targeted therapeutic strategies to complement and synergize with other anticancer treatments. Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated macrophages (TAMs) contribute to tumour progression at different levels: by promoting genetic instability, nurturing cancer stem cells, supporting metastasis, and taming protective adaptive immunity. TAMs can exert a dual, yin–yang influence on the effectiveness of cytoreductive therapies (chemotherapy and radiotherapy), either antagonizing the antitumour activity of these treatments by orchestrating a tumour-promoting, tissue-repair response or, instead, enhancing the overall antineoplastic effect. TAMs express molecular triggers of checkpoint proteins that regulate T-cell activation, and are targets of certain checkpoint-blockade immunotherapies. Other macrophage-centred approaches to anticancer therapy are under investigation, and include: inhibition of macrophage recruitment to, and/or survival in, tumours; functional re-education of TAMs to an antitumour,

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't see how the site brings in money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, google, scholar, cas, cancer, central, macrophages, macrophage, cells, cell, tumor, res, tumorassociated, nature, immunol, mantovani, med, nat, patients, oncol, article, immunity, therapy, factor, clin, antitumor, blockade, targeting, science, immune, receptor, anticancer, human, antibody, metastasis, survival, rev, breast, natl, content, progression, chemotherapy, inhibition, exp, monocytes, pancreatic, lymphoma, clinical, microenvironment, tumour,

Topics {✒️}

nature portfolio journals permissions reprints nature portfolio privacy policy colony-stimulating factor-1 receptor ipilimumab-dependent cell-mediated cytotoxicity pi3k/akt/rhoa signaling pathway cox/mpges-1/pge2 pathway depicts advertising european research council worldwide cancer research macrophage colony-stimulating factor-1 macrophage colony-stimulating factor anti-csf-1r antibody reveals antibody-dependent cellular cytotoxicity social media cancer research tenosynovial giant-cell tumor anti-pd-l1 antibody mpdl3280a anti-cd47 antibody-mediated phagocytosis colony-stimulating factor-1 open-label cancer stem/initiating cells author information authors nature+ nature 454 nature 228 nature 475 nature 515 nature myeloid-derived suppressor cells t-cell checkpoint immunotherapy targeting cgas-sting pathway csf1 receptor targeting author correspondence intra-tumoral infiltrating macrophages facilitate breast-tumour metastasis her2-positive breast cancer provide tools tam-focused therapeutic strategies macrophage-activating signal factor hypoxia enhanced mdsc-mediated anti-cd47 antibody synergizes small-cell lung cancer csf1r kinase tumour-targeting monoclonal antibodies antitumor t-cell immunity vegf receptor flt-1 phase ii study microsatellite-unstable gastric carcinoma

Questions {❓}

  • Inflammation and cancer: back to Virchow?
  • Innate inflammation and cancer: is it time for cancer prevention?
  • Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tumour-associated macrophages as treatment targets in oncology
         description: Tumour-associated macrophages (TAMs) are key drivers of tumour-promoting inflammation and cancer progression, and are important determinants of responsiveness to a range of therapies. Herein, the authors summarize the roles of TAMs in cancer, and discuss the potential of TAM-targeted therapeutic strategies to complement and synergize with other anticancer treatments. Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated macrophages (TAMs) contribute to tumour progression at different levels: by promoting genetic instability, nurturing cancer stem cells, supporting metastasis, and taming protective adaptive immunity. TAMs can exert a dual, yin–yang influence on the effectiveness of cytoreductive therapies (chemotherapy and radiotherapy), either antagonizing the antitumour activity of these treatments by orchestrating a tumour-promoting, tissue-repair response or, instead, enhancing the overall antineoplastic effect. TAMs express molecular triggers of checkpoint proteins that regulate T-cell activation, and are targets of certain checkpoint-blockade immunotherapies. Other macrophage-centred approaches to anticancer therapy are under investigation, and include: inhibition of macrophage recruitment to, and/or survival in, tumours; functional re-education of TAMs to an antitumour, 'M1-like' mode; and tumour-targeting monoclonal antibodies that elicit macrophage-mediated extracellular killing, or phagocytosis and intracellular destruction of cancer cells. The evidence supporting these strategies is reviewed herein. We surmise that TAMs can provide tools to tailor the use of cytoreductive therapies and immunotherapy in a personalized medicine approach, and that TAM-focused therapeutic strategies have the potential to complement and synergize with both chemotherapy and immunotherapy.
         datePublished:2017-01-24T00:00:00Z
         dateModified:2017-01-24T00:00:00Z
         pageStart:399
         pageEnd:416
         sameAs:https://doi.org/10.1038/nrclinonc.2016.217
         keywords:
            Cancer immunotherapy
            Cancer microenvironment
            Translational research
            Tumour biomarkers
            Tumour immunology
            Medicine/Public Health
            general
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrclinonc.2016.217/MediaObjects/41571_2017_Article_BFnrclinonc2016217_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrclinonc.2016.217/MediaObjects/41571_2017_Article_BFnrclinonc2016217_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrclinonc.2016.217/MediaObjects/41571_2017_Article_BFnrclinonc2016217_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrclinonc.2016.217/MediaObjects/41571_2017_Article_BFnrclinonc2016217_Fig4_HTML.jpg
         isPartOf:
            name:Nature Reviews Clinical Oncology
            issn:
               1759-4782
               1759-4774
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Alberto Mantovani
               affiliation:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                     address:
                        name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                        type:PostalAddress
                     type:Organization
                     name:Humanitas University
                     address:
                        name:Humanitas University, Rozzano, Milan, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Federica Marchesi
               affiliation:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                     address:
                        name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Milan
                     address:
                        name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alberto Malesci
               affiliation:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                     address:
                        name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Milan
                     address:
                        name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Luigi Laghi
               affiliation:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                     address:
                        name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Paola Allavena
               affiliation:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                     address:
                        name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                        type:PostalAddress
                     type:Organization
                     name:Humanitas University
                     address:
                        name:Humanitas University, Rozzano, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tumour-associated macrophages as treatment targets in oncology
      description: Tumour-associated macrophages (TAMs) are key drivers of tumour-promoting inflammation and cancer progression, and are important determinants of responsiveness to a range of therapies. Herein, the authors summarize the roles of TAMs in cancer, and discuss the potential of TAM-targeted therapeutic strategies to complement and synergize with other anticancer treatments. Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated macrophages (TAMs) contribute to tumour progression at different levels: by promoting genetic instability, nurturing cancer stem cells, supporting metastasis, and taming protective adaptive immunity. TAMs can exert a dual, yin–yang influence on the effectiveness of cytoreductive therapies (chemotherapy and radiotherapy), either antagonizing the antitumour activity of these treatments by orchestrating a tumour-promoting, tissue-repair response or, instead, enhancing the overall antineoplastic effect. TAMs express molecular triggers of checkpoint proteins that regulate T-cell activation, and are targets of certain checkpoint-blockade immunotherapies. Other macrophage-centred approaches to anticancer therapy are under investigation, and include: inhibition of macrophage recruitment to, and/or survival in, tumours; functional re-education of TAMs to an antitumour, 'M1-like' mode; and tumour-targeting monoclonal antibodies that elicit macrophage-mediated extracellular killing, or phagocytosis and intracellular destruction of cancer cells. The evidence supporting these strategies is reviewed herein. We surmise that TAMs can provide tools to tailor the use of cytoreductive therapies and immunotherapy in a personalized medicine approach, and that TAM-focused therapeutic strategies have the potential to complement and synergize with both chemotherapy and immunotherapy.
      datePublished:2017-01-24T00:00:00Z
      dateModified:2017-01-24T00:00:00Z
      pageStart:399
      pageEnd:416
      sameAs:https://doi.org/10.1038/nrclinonc.2016.217
      keywords:
         Cancer immunotherapy
         Cancer microenvironment
         Translational research
         Tumour biomarkers
         Tumour immunology
         Medicine/Public Health
         general
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrclinonc.2016.217/MediaObjects/41571_2017_Article_BFnrclinonc2016217_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrclinonc.2016.217/MediaObjects/41571_2017_Article_BFnrclinonc2016217_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrclinonc.2016.217/MediaObjects/41571_2017_Article_BFnrclinonc2016217_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrclinonc.2016.217/MediaObjects/41571_2017_Article_BFnrclinonc2016217_Fig4_HTML.jpg
      isPartOf:
         name:Nature Reviews Clinical Oncology
         issn:
            1759-4782
            1759-4774
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Alberto Mantovani
            affiliation:
                  name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                  address:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                     type:PostalAddress
                  type:Organization
                  name:Humanitas University
                  address:
                     name:Humanitas University, Rozzano, Milan, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Federica Marchesi
            affiliation:
                  name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                  address:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Milan
                  address:
                     name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alberto Malesci
            affiliation:
                  name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                  address:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Milan
                  address:
                     name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Luigi Laghi
            affiliation:
                  name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                  address:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Paola Allavena
            affiliation:
                  name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
                  address:
                     name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
                     type:PostalAddress
                  type:Organization
                  name:Humanitas University
                  address:
                     name:Humanitas University, Rozzano, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Clinical Oncology
      issn:
         1759-4782
         1759-4774
      volumeNumber:14
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
      address:
         name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
         type:PostalAddress
      name:Humanitas University
      address:
         name:Humanitas University, Rozzano, Milan, Italy
         type:PostalAddress
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
      address:
         name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
         type:PostalAddress
      name:University of Milan
      address:
         name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
         type:PostalAddress
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
      address:
         name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
         type:PostalAddress
      name:University of Milan
      address:
         name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
         type:PostalAddress
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
      address:
         name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
         type:PostalAddress
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
      address:
         name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
         type:PostalAddress
      name:Humanitas University
      address:
         name:Humanitas University, Rozzano, Milan, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Alberto Mantovani
      affiliation:
            name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
            address:
               name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
               type:PostalAddress
            type:Organization
            name:Humanitas University
            address:
               name:Humanitas University, Rozzano, Milan, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Federica Marchesi
      affiliation:
            name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
            address:
               name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
               type:PostalAddress
            type:Organization
            name:University of Milan
            address:
               name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Alberto Malesci
      affiliation:
            name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
            address:
               name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
               type:PostalAddress
            type:Organization
            name:University of Milan
            address:
               name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Luigi Laghi
      affiliation:
            name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
            address:
               name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Paola Allavena
      affiliation:
            name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
            address:
               name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
               type:PostalAddress
            type:Organization
            name:Humanitas University
            address:
               name:Humanitas University, Rozzano, Milan, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
      name:Humanitas University, Rozzano, Milan, Italy
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
      name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
      name:Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
      name:Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Milan, Italy
      name:Humanitas University, Rozzano, Milan, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(781)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

6.09s.